Skip to main content
Premium Trial:

Request an Annual Quote

Viome Raises $54M to Advance mRNA Platform for Diagnosis, Drug Development

NEW YORK – Viome Life Sciences said Wednesday that it has raised $54 million in pre-series C convertible funding with participation from existing and new investors. Added to prior funding, including a series B round in November 2019, the company said it has raised over $125 million in total.

This latest influx will support expanded clinical research focused on aggressive cancers and chronic diseases, with an eventual goal of developing early-stage diagnostics and therapeutics using the firm's mRNA platform. Initially focused on direct-to-consumer, gut microbiome-based wellness testing, Viome has more recently expanded its ambitions to these broader areas.

Cancers in which the firm is researching its technology include pancreatic cancer, bile cancer, breast cancer, gastrointestinal cancers, gynecological cancers, and head, neck, and shoulder cancers. The company said it also has active therapeutics efforts in Alzheimer's, metabolic diseases, and mental health.

Viome and GlaxoSmithKline recently announced an agreement to expand a clinical validation partnership to develop new therapeutic interventions for select cancers and autoimmune diseases.

Returning investors in the pre-series C financing included Khosla Ventures, West River Group, Glico, Physician Partners, and Bold Capital Group. Ocgrow Ventures also participated as a new investor, and Viome said Harish Consul, Ocgrow's founder and CEO, will consequently serve as an observer on its board of directors.